An Open Label Study to Evaluate G17DT Compared to Gemcitabine
In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.
Pancreatic Cancer
BIOLOGICAL: G17DT|DRUG: Gemcitabine
Survival, Survival in days measured starting at Baseline, Baseline (Week 0) up to Week 52 or death.
Tumor Response, The proportion of patients having an objective tumor response using Computed Tomography (CT) and the Response Evaluation Criteria In Solid Tumors (RECIST).

(RECIST) guidelines, Weeks 0, 12, 24, 36 and 52|Quality of Life, Quality of life measured using Cancer Quality of Life Questionnaire EORTC-QLQC30 questionnaire, Weeks 0, 6, 12, 24, 36 and 52|Quality of Life, Quality of life measured using and the EORTC QLQ-PAN26 questionnaire, Weeks 0, 6, 12, 24, 36 and 52|Karnofsky Performance Status, Functional impairment assessment using the Karnofsky Performance Scale Index, Week 0 to Week 52|Gastrin-17 Antibodies, Antibody assessment to determine serum levels of Gastrin -17 antibodies, Weeks 0, 6, 12, 24, 36 and 52
In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.